Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]

  • In development
  • GID-TA10623
  • Expected publication date: TBC

Status:
In progress
Decision:
Selected
Process:
TA
ID number:
2730

Timeline

Key events during the development of the guidance:

Date Update
06 February 2020 In progress. Topic is now in progress

For further information on our processes and methods, please see our CHTE processes and methods manual